266
Participants
Start Date
November 30, 2014
Primary Completion Date
October 26, 2018
Study Completion Date
October 26, 2018
TV003
10\^3 plaque forming units (PFU) of rDEN1 delta 30, 10\^3 PFU of rDEN2/4 delta 30(ME), 10\^3 PFU of rDEN3 delta 30/31-7164, and 10\^3 PFU of rDEN4 delta 30 to be administered as 0.5 mL by subcutaneous injection in the deltoid region of the upper arm or the thigh in pediatric participants
Placebo for TV003
To be administered as 0.5 mL by subcutaneous injection in the deltoid region of the upper arm or the thigh in pediatric participants
Phramongkutklao Hospital, Bangkok
National Institute of Allergy and Infectious Diseases (NIAID)
NIH